-
Letter to Register Shareholders - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
Letter to Non-Register Shareholders - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 20242024-10-02
-
Notification Letter and Request Form to Non-registered Holders2024-09-26
-
Notification Letter and Reply Form to Registered Shareholders2024-09-26
-
INTERIM REPORT 20242024-09-26
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 20242024-09-02
-
ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS2024-08-27
-
INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 20242024-08-27
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20242024-08-27
-
VOLUNTARY ANNOUNCEMENT - B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION2024-08-20